Tourism Australia Staff Conference, December 2022 © Tourism Australia

Our Organisation

Goat Island, Sydney Harbour, New South Wales © Destination NSW

Our Careers

Kangaroo at Crowdy Bay National Park, New South Wales © Tourism Australia

Tourism Statistics

Balloons and arboretum, Canberra, Australian Capital Territory © VisitCanberra

Industry Resources

Arkaba Walk, Flinders Ranges, SA.

Media Resources

Sydney, New South Wales © Tourism Australia

Travel Trade Hub

Cape to Cape Track, Margaret River, WA © Tourism Western Australia

News Stories

Murrays Beach, Jervis Bay, New South Wales ©  Destination NSW

Newsletters

Destination Australia Conference 2020 © Tourism Australia

Industry Events

Dreamtime 2017, Brisbane, Queensland © Tourism Australia, Remco Jansen

Business Events

Hill Inlet, Whitsunday Islands, Queensland © Tourism and Events Queensland

  • Share Share on Facebook Share on Twitter Share on WhatsApp Copy Link

Our vision is aligned to our core values support at Tourism Australia. They are the essence of our identity and provide the guiding principles to our behaviour and the relationships we have with our customers and partners.

  • We think big and without borders 
  • We make each other better 
  • We do the right thing 
  • We only do work that makes a difference 
  • We're obsessed with telling the Australian story

Tourism Australia Act 2004

Tourism Australia is a corporate Commonwealth entity and was established by the Tourism Australia Act 2004 "> Tourism Australia Act 2004 .

Under section 6 of the Tourism Australia Act 2004 , Tourism Australia’s main objectives are:

  • To influence people to travel to Australia, including for events, 
  • To influence people travelling to Australia to also travel throughout Australia, 
  • To influence Australians to travel throughout Australia, including for events, 
  • To help foster a sustainable tourism industry in Australia, and
  • To help increase the economic benefits to Australia from tourism.

Cygnet Bay Pearl Farm, Dampier Peninsula, Western Australia © Tourism Western Australia

Reimagining the Visitor Economy

Discover more.

Tourism Australia Staff Conference, December 2022 © Tourism Australia

We use cookies on this site to enhance your user experience. Find out more .

By clicking any link on this page you are giving your consent for us to set cookies.

Acknowledgement of Country

Indigenous symbol - Natural Beauty

We acknowledge the Traditional Aboriginal and Torres Strait Islander Owners of the land, sea and waters of the Australian continent, and recognise their custodianship of culture and Country for over 60,000 years.

*Disclaimer:  The information on this website is presented in good faith and on the basis that Tourism Australia, nor their agents or employees, are liable (whether by reason of error, omission, negligence, lack of care or otherwise) to any person for any damage or loss whatsoever which has occurred or may occur in relation to that person taking or not taking (as the case may be) action in respect of any statement, information or advice given in this website. Tourism Australia wishes to advise people of Aboriginal and Torres Strait Islander descent that this website may contain images of persons now deceased.

Information Publication Scheme logo

Tourism Australia Act 2004.

  • About ECOLEX
  • User Agreement
  • Acknowledgments
  • Take a tour

Tourism Act 2004 (No. 19 of 2004).

This Act provides rules for the tourist industry and makes provision for the establishment of the Tourist Authority and the licensing of tourist enterprises.

References - Legislation

Tourism (amendment) act 2005 (no. 10 of 2005)..

Keyword: Fishing vessel, Authorization/permit, Non-commercial fishing, Tourism

Source:  FAO, FAOLEX

Tourism Authority Act 2006 (No. 32 of 2006).

Keyword: Tourism, Institution

Delete record "Tourism Act 2004 (No. 19 of 2004)."

Access information on Multilateral Environmental Agreements

Tourism act 2004 (no. 19 of 2004)..

This content is exclusively provided by FAO / FAOLEX / ECOLEX

This website is managed by the Office of the Attorney-General ( ‘Office’ ) for the purpose of providing information free of charge for the benefit of the public.

This website contains information that is intended to simplify the law for ease of comprehension. Errors or omissions can occur in the preparation of web pages and materials may be maliciously vandalised. Accordingly, no assurance is given as to the accuracy of any representation, statement, information or advice on this website.

The Office does not guarantee, and accepts no legal liability whatsoever arising from or connected to, the accuracy, reliability, currency or completeness of any material contained on this website or on any linked site.

The information on this website is provided solely on the basis that users will be responsible for making their own assessment of the materials presented. Therefore, before relying on the material on this website, users should exercise their own skill and care with the use of this website and carefully evaluate the accuracy, reliability, currency, completeness and relevance of the material on this website or on any linked site for their purposes.

This website is not a substitute for independent legal or other professional advice and users should obtain appropriate independent professional advice relevant to their particular circumstances.

The Office, the Fijian Government and all employees and agents of the Office and/or of the Fijian Government will not be responsible or liable for any loss, damage or injury (including death) however caused (whether caused by any negligent or other unlawful act or omission of, by or on the part of the Office, the Fijian Government, or any agent or employee of the Office or the Fijian Government) arising from the use of or reliance by any person on any information, data or advice (including incomplete, out of date, wrong, inaccurate or misleading information, data or advice) expressed or implied in, or coming from, this website.

tourism act 2004

  • The Fijian Constitution
  • Consolidated Laws
  • Laws as Published
  • Omitted & Repealed Laws
  • Publications & Sales
  • [TF 1] s 1 Short title and commencement
  • [TF 2] s 2 Interpretation
  • [TF 3] s 3 Establishment of the corporation
  • [TF 4] s 4 Object of the corporation
  • [TF 5] s 5 Functions of the corporation
  • [TF 6] s 6 Establishment of the Board
  • [TF 7] s 7 Powers of the Board
  • [TF 8] s 8 Meetings of the Board
  • [TF 9] s 9 Disclosure of interest
  • [TF 10] s 10 Remuneration of members of the Board and committees
  • [TF 11] s 11 Appointment of Chief Executive and other staff
  • [TF 12] s 12 Power to give directions
  • [TF 13] s 13 Annual statements
  • [TF 14] s 14 Power to raise loans
  • [TF 15] s 15 Accounts and audit
  • [TF 16] s 16 Annual report
  • [TF 17] s 17 Exemption of liability
  • [TF 18] s 18 Delegation of powers
  • [TF 19] s 19 Regulations
  • [TF 20] s 20 Repeal and savings

MCCI

  • News & Events
  • Tax Free Shopping
  • GS1 Mauritius
  • Certificate of Origin
  • Contact your representative
  • Trade platform
  • Become a member
  • MEMBERS LOGIN

Legislations

Legislations

  • Inside Mauritius
  • Code de Procédure Civile
  • Convention Recognition Foreign Arbitral Awards
  • International Arbitration Act 2009
  • Investment Disputes Enforcement of Awards Act 1969
  • Code de Commerce
  • THE BUSINESS FACILITATION (MISCELLANEOUS PROVISIONS) ACT 2017
  • Code Civil Mauricien
  • The Business Registration Act 2002 Updated
  • The Companies Act 2001
  • The Local Government Act 2011
  • The Small Enterprises and Handicraft Development Authority Act 2005
  • Competition Act 2007
  • Competition Commission Rules of Procedure 2009
  • The Consumer Protection Act 1991 (Updated)
  • The Consumer Protection (Price and Supplies Control) Act 1998 Updated
  • Consumer Protection (Maximum Price of Essential Goods) Regulations 2021 – GN 158 of 2021
  • THE CONSUMER PROTECTION (PRICE AND SUPPLIES CONTROL) (AMENDMENT) ACT 2012
  • Consumer Protection (Shelf Life of Imported Food Products) Regulations 2020
  • Consumer Protection (Consumer Goods) (Maximum Mark-Up) Regulations No 150 of1998 (Updated)
  • Consumer Protection (Consumer Goods) (Maximum Mark-up) (Amendment No.1 ) No. 59 Regulations 2020
  • Consumer Protection (Consumer Goods) (Maximum Mark-up) (Amendment No.2 ) No. 80 Regulations 2020
  • Consumer Protection (Consumer Goods) (Maximum Mark-up) (Amendment No.3 ) No. 95 Regulations 2020
  • Consumer Protection (Consumer Goods) (Maximum Mark-Up) (Amendment No. 4) Regulations 2020
  • Consumer Protection (Consumer Goods) (Maximum Mark-Up) (Amendment) No 145 Regulations 2017
  • Consumer Protection (Consumer Goods) (Maximum Mark-up) (Amendment) No 238 Regulations 2017.pdf
  • Consumer Protection (Maximum Mark-Up) (Amendment) No 83 Regulations 2018 (Inroduction of Blood Glucose Strips).pdf
  • Consumer Protection (Maximum Mark-up) (Amendment) (Provision for Special Allowance) No. 95 Regulations 2020
  • Consumer Protection (Control of Imports) Regulations 2017 -updated
  • The Consumer Protection (Control of Imports) (Amendment) Regulations 2017
  • Consumer Protection (Control of Imports) (Amendment) No 81 Regulations 2018 (Second-Hand Vehicles)
  • Consumer Protection (Control of imports) (Amendment) No 91 Regulations 2019 (Incandescent lamps of 75 watts)
  • Consumer Protection (Control of Price of Fertilizers) Regulations 1998
  • Consumer Protection (Export Control) Regulations 2000
  • Consumer Protection (Export Control) (Amendment) No 56 Regulations 2017
  • Consumer Protection (Export Control) (Amendment) No 158 Regulations 2017
  • Consumer Protection (Importation and Sale of Second-hand Motor Vehicles) Regulations 2004
  • Consumer Protection (Importation and Sale of Second-hand Motor Vehicles) Amendment Regulations 2017
  • Consumer Protection (Maximum Recommended Retail Price) (Code of Practice) Regulations 2008
  • Consumer Protection (Licensing of Authorised Dealers in Imported Second-hand Motor Vehicles) 2003
  • Consumer Protection (Price Label) Regulations 1998
  • Consumer Protection (Product Advertisement and Promotion) Regulations 2012
  • CONSUMER PROTECTION (SCRAP METAL) REGULATIONS 2019
  • Consumer Protection (Use of Liquefied Petroleum Gas in Small Cylinders) Regulations 2012
  • Consumer Protection, (Provision for Incidental Matters) Regulations 2006
  • Export to the United States of America (AGOA) Regulations 2000
  • EXPORT TO THE UNITED STATES OF AMERICA (AGOA) (AMENDMENT)REGULATIONS No 208 of 2004
  • Laser Pointers (Safety) Regulations 2007
  • Plastic and Polyethylene Pipes and Fittings (Mauritius Standard Specifications) Regulations 2007
  • Toys (Safety) Regulations 1994
  • Toys (Safety) (Amendment) No 85 Regulations 2018 (Importation for personal use).pdf
  • Consumer Protection (Price and Supplies Control) (Amendment of Schedule) No.79 Regulations 2020
  • Consumer Protection (Consumer Goods) (Maximum Mark-up) (Amendment No.2) No. 80 Regulations 2020
  • Consumer Protection (Control of Fairs) Regulations 2016 updated as at May 2016
  • Consumer Protection (Control of Fairs) (Amendment) No 110 Regulations 2016
  • Consumer Protection (Control of Fairs) (Amendment) No 204 Regulations 2016
  • The Consumer Protection (Safety Requirements) Regulations 2017
  • Consumer Protection (Safety Requirements) (Amendment) RegulationsNo 200 of 2017
  • Consumer Protection (Safety Requirements) (Amendment) No 84 Regulations 2018 (Importation for personal use).pdf
  • Bread (Control of Manufacture and Sale) Regulations No 4 of 1988
  • Bread (Control of Manufacture and Sale) (Amendment) Regulations No 110 of 2017
  • The consumer protection consumer goods maximum mark up amendment regulations 2022
  • Covid-19 (Miscellaneous Bill) 2020
  • The Customs Act (Updated as at 22 May 2020)
  • The Customs Tariff Act (updated).pdf
  • Customs Tariff (Amendment of Schedule) (No 261) Regulations 2016
  • Customs Tariff (Amendment of Schedule) (No 164) Regulations 2016
  • Customs Tariff (Amendment of Schedule) Regulations No138 of 2016
  • The Excise Act (updated).pdf
  • Customs (Cargo Community System) Regulations 2008
  • Customs (Certificate of Origin under IOC Trade Protocol)
  • Customs (Compoundable Offence and Compounding Amount) Regulations 2012
  • Customs (Export Licence for Sugar to European Community)
  • Customs (Export to the Southern African Development Community Certificate) Regulations
  • Customs (Export to the Southern African Development Community Certificate) (Amendment) Regulations No 181 of 2009
  • Customs (Export to Pakistan) Regulations 2014
  • Customs (Maximum Number of Customs House Brokers) Regulations 2008
  • Customs (Movement Certificate EUR 1) Regulations 2005
  • CUSTOMS (MOVEMENT CERTIFICATE EUR 1) (AMENDMENT) REGULATIONS No 15 of 2006
  • CUSTOMS (MOVEMENT CERTIFICATE EUR 1) (AMENDMENT) REGULATIONS No 28 of 2008
  • Customs (Movement Certificate EUR 1) (Amendment) Regulations No 196 of 2013
  • CUSTOMS (MOVEMENT CERTIFICATE EUR 1) (AMENDMENT) REGULATIONSNo 184 of 2009
  • Customs (Suspension of Permit or Authorisation) Regulations 2009
  • Customs (Use of Computer) Regulations 1997
  • CUSTOMS (USE OF COMPUTER) (AMENDMENT) REGULATIONS No 16 of 2006
  • Customs (Use of Computer) (Amendment) Regulations No 16 of 2013
  • Customs (Use of Computer) (Amendment) Regulations No 122 of 2003
  • CUSTOMS (USE OF COMPUTER) (AMENDMENT) REGULATIONS No 160 of 2010
  • CUSTOMS (USE OF COMPUTER) (AMENDMENT) REGULATIONS No 173 of 2007
  • CUSTOMS (USE OF COMPUTER) (AMENDMENT) REGULATIONS No 183 of 2009
  • Customs (Use of Computer) (Amendment) Regulations No 244 of 2016
  • Customs Bills (Processing Fees) Regulations 1989
  • Customs Bills (Processing Fees) (Amendment No 2) Regulations No 128 of 1997
  • Customs Bills (Processing Fees) (Amendment) Regulations No 34 of 1990
  • Customs Bills (Processing Fees) (Amendment) Regulations No 37 of 1997
  • Customs Bills (Processing Fees) (Amendment) Regulations No 177 of 1990
  • Excise (CO2 Levy or CO2 Rebate) Regulations 2013
  • Customs Regulations 1989
  • Customs (Amendment) Regulations No 184 of 2016
  • Customs (Amendment) Regulations No 197 of 2017
  • Customs (Amendment) Regulations No 266 of 2016
  • Excise (Valuation of Motor Vehicles) Regulations 2003
  • EXCISE (Valuation of Motor Vehicles) (Amendment) Regulations No 97 of 2009
  • Excise (Valuation of Motor Vehicles) (Amendment) Regulations No 165 of 2016
  • Excise Regulations 1994
  • Excise (Amendment No. 2) Regulations No 205 2016
  • Excise (Amendment of Schedule) Regulations N0 218 of 2016
  • Excise (Amendment) Regulations No 152 of 2016
  • Excise (Amendment) Regulations No 183 of 2017
  • Excise (Biodegradable and non-biodegradable Plastic Containers) (Amendment) Regulations No 72 of 2019
  • Excise (Biodegradable and non-biodegradable Plastic Containers) (Amendment of Schedule) Regulations No 73 of 2019.
  • Regulations - Excise stamps on Alcoholic Products
  • Energy Efficiency Levy - Amendments to Customs Tariff Act - Annex 1.pdf
  • Energy Efficiency Levy - Amendments to Customs Tariff Act - Annex 2.pdf
  • The Fair Trading Act 1980 (updated)
  • Basmati Rice (Control of Sale) Regulations 2012
  • Commodities (Indication of Origin) Regulations 1981
  • Commodities (Indication of Origin) (Amendment) Regulations No 50 of 2005
  • Prepackaged Food Regulations 1989
  • Prepackaged Food (Amendment) Regulations No 34 1994
  • Prepackaged Food (Amendment) Regulations No 100 of 1998
  • Prepackaged Food (Amendment) Regulations No 186 of 1990
  • Steel Bars and Steel Wires (Mauritian Standard Specifications) Regulations 1988
  • Hot Dip Galvanised Articles (Mauritian Standard Specifications) Regulations 1989 (updated)
  • Finance Act 2007
  • The Finance (Miscellaneous Provisions) Act 2013
  • The Food Act 1998
  • THE FOOD (AMENDMENT) ACT 2004
  • Food Regulation 1999-updated
  • Food (Amendment) Regulations No 155 of 2017
  • Food (Amendment No. 2) Regulations No188 of 2017
  • The Freeport Act (updated).pdf
  • Freeport Regulations 2005
  • Freeport (Amendment of Schedule) Regulations No 4 of 2015
  • Freeport (Amendment of Schedule) Regulations No 195 of 2016
  • The Hire Purchase and Credit Sale Act 1964
  • Hire Purchase and Credit Sale (Charges) (Amendment) Regulations 2012
  • Hire Purchase and Credit Sale (Charges) Regulations 2000
  • Hire Purchase and Credit Sale (Charges) (Amendment) Regulations 2015
  • Hire Purchase and Credit Sale (Charges) Amendment Regulations 2018.pdf
  • Electronic Transaction Act 2000
  • Data Protection Act 2004
  • Computer Misuse and Cybercrime Act 2003
  • Copyright Act
  • Patents Industrial Designs Trademarks Act 2003
  • Protection Against Unfair Practices 2003
  • Employment Relations Act
  • THE EMPLOYMENT RELATIONS (AMENDMENT) ACT 2019.pdf
  • THE WORKERS' RIGHTS Act 2019.pdf
  • The Tailoring Trade (Remuneration) Regulations 2019.pdf
  • The Travel Agents and Tour Operators Workers (Remuneration) Regulations 2019.pdf
  • The Attorneys' and Notaries' Workers (Remuneration) Regulations 2019.pdf
  • The Pre-Primary School Employees (Remuneration) Regulations 2019.pdf
  • The Tea Industry Workers (Remuneration) Regulations 2019.pdf
  • The Private Security Services Employees (Remuneration) Regulations 2019.pdf
  • The Workers' Rights (Amendment of Schedule) Regulations 2019.pdf
  • The Road Haulage Industry (Remuneration) Regulations 2019.pdf
  • The Livestock Workers (Remuneration) Regulations 2019.pdf
  • The Workers' Rights (Atypical Work) Regulations 2019.pdf
  • The Export Enterprises (Remuneration) Regulations 2019.pdf
  • The Banks Fishermen and Frigo-workers (Remuneration) Regulations 2019.pdf
  • The Private Hospitals and Other Related Health Services (Remuneration) Regulations 2019.pdf
  • The Cinema Employees (Remuneration) Regulations 2019.pdf
  • The Private Secondary Schools Employees (Remuneration) Regulations 2019.pdf
  • The Sugar Industry (Agricultural Workers) (Remuneration) Regulations 2019.pdf
  • The Workers' Rights (Seed Capital) Regulations 2019.pdf
  • The Information and Communicatio Technologies and Other Related Services (Remuneration) Regulations 2019.pdf
  • The Newspapers and Periodicals Employees (Remuneration) Regulations 2019.pdf
  • The Salt Manufacturing Industry (Remuneration) Regulations 2019.pdf
  • The Cleaning Enterprises (Remuneration) Regulations 2019.pdf
  • The Printing Industry (Remuneration) Regulations 2019.pdf
  • The Light Metal and Wooden Furniture Workshops (Remuneration) Regulations 2019.pdf
  • The Public Transport (Buses) Workers (Remuneration) Regulations 2019.pdf
  • The Sugar Industry (Non-Agricultural Workers) (Remuneration) Regulations 2019.pdf
  • The Field-crop and Orchard Workers (Remuneration) Regulations 2019.pdf
  • The Factory Employees (Remuneration) Regulations 2019.pdf
  • The Domestic Workers (Remuneration) Regulations 2019.pdf
  • The Baking Industry (Remuneration) Regulations 2019.pdf
  • The Blockmaking, Construction, Stone Crushing and Related Industries (Remuneration) Regulations 2019.pdf
  • The Electrical, Engineering and Mechanical Workshops (Remuneration) Regulations 2019.pdf
  • The Catering and Tourism Industries (Remuneration) Regulations 2019.pdf
  • The Distributive Trades (Remuneration) Regulations 2019.pdf
  • The Office Attendants (Remuneration) Regulations 2019.pdf
  • The Legal Metrology Act 1985
  • Legal Metrology (Pre-packed Commodities) Regulations 2006
  • Legal Metrology (Pre-packed Commodities) (Amendment) Regulations No 109 of 2017
  • Legal Metrology (Pre-packed Commodities) (Amendment No. 2) Regulations No 175 of 2017
  • The Mauritius Revenue Authority Act 2004
  • Mauritius Revenue Authority (Review of Assessment) (Waiver of Right) Regulations
  • The Animal Diseases Act 1925
  • The Essential Commodities Act 1991
  • The Mauritius Agricultural Marketing Act 1963
  • The Non-Citizens (Property Restriction) Act 1975
  • The Plant Protection Act 2006
  • Trade (Anti-Dumping and Countervailing Measures) Act 2010
  • The Pharmacy Act 1983
  • National Agricultural Products Regulatory Office Act 2013
  • National Agricultural Products Regulations 2013
  • Animal Diseases Regulations 1925
  • Therapeutic Substances Regulations 1937
  • Mauritius Agricultural Marketing (Controlled Products) Regulations 2013
  • Public Health (Restrictions on Tobacco Products) Regulations 2008
  • General Retailers (Sale of Simple Medicines) Regulations 1989
  • Pharmacy and Poisons (Prohibition of Harmful Drugs) Regulations 1982
  • Sugar Cane (Specification of Varieties) (Amendment) Regulations 2007
  • Energy Efficiency (Labelling of Regulated Machinery) Regulations 2017.pdf
  • Public health restrictions on tobacco products regulations 2022
  • Jewellery Act 2007
  • The Financial Services Act 2007
  • Tourism Act 2004
  • Tourism Authority Act 2006
  • The Value Added Tax Act 1998
  • Value Added Tax (Solidarity Levy) Regulations 2006
  • Value Added Tax Regulations 1998

June 1995 Australian Chamber of Commerce and Industry (ACCI)

September 2014 Austrian Federal Economic Chamber

April 1997 China Council for the Promotion of International Trade (CCPIT) - Beijing China International Economic and Trade Arbitration Commission - Shanghai November 1998 CCPIT Guangdong Sub-Council September 2008 CCPIT Qingdao May 2007 CCPIT Qingdao

April 2017 L´Union des Chambres de Commerce, d´Industrie et d´Agriculture

August 2008 Chamber of Commerce of Djibouti

September 2015 Estonia Chamber of Commerce and Industry

September 1996 l’Assemblée des Chambres Françaises de Commerce et d’Industrie (ACFCI)

November 1985 Federation of Indian Chambers of Commerce and Industry (FICCI) May 1996 Confederation of Indian Industry (CII) June 1995 Tamil Nadu Chamber of Commerce and Industry January 2004 India International Trade Center May 2004 Seafood Exporters Association of India October 2005 Seafood Exporters Association of India

January 2011 The Kenya National Chamber of Commerce and Industry (KNCCI)

November 2004 Fédération des Chambres de Commerce, d’Industrie, d’Artisanat et d’Agriculture de Madagascar

August 1994 The National Chamber of Commerce and Industry of Malaysia June 2005 Malaysian Associated Indian Chambers of Commerce and Industry

September 2012 Chamber of Commerce of Mozambique

June 2019 Nigeria Association of Chambers of Commerce and Industry, Mines and Agriculture

October 2004 The Federation of Pakistan Chambers of Commerce and Industry (FPCCI)

Réunion

June 1995 Chambre of Commerce and d’Industrie de la Réunion March 2002 L’Association pour le Développement Industriel de la Réunion

May 2007 Chamber of Commerce and Industry of the Russian Federation

November 2005 Seychelles Chamber of Commerce and Industry April 2014 Seychelles Chamber of Commerce and Industry

September 2018 Slovak Chamber of Commerce and Industry (SCCI)

South Africa

September 2016 South African Chamber of Commerce and Industry

May 2004 National Chamber of Commerce of Sri Lanka

September 2017 Taiwan External Trade Development Council

January 2011 The Tanzania Chamber of Commerce, Industry and Agriculture (TCCIA)

August 2004 The Federation of Thai Industries (F.T.I) February 2013 TUSKON

August 2014 DEIK (Foreign Economic Relations Board) TOBB (The Union of Chambers and Commodity Exchanges of Turkey)

Legislations

You are using an outdated browser. Upgrade your browser today or install Google Chrome Frame to better experience this site.

  • Section 4 - Scuba Diving: Decompression Illness & Other Dive-Related Injuries
  • Section 4 - Mosquitoes, Ticks & Other Arthropods

High Elevation Travel & Altitude Illness

Cdc yellow book 2024.

Author(s): Peter Hackett, David Shlim

Acclimatization

Altitude illness, medications, preventing severe altitude illness or death.

Typical high-elevation travel destinations include Colorado ski resorts with lodgings at 8,000–10,000 ft (≈2,440–3,050 m); Cusco, Peru (11,000 ft; ≈3,350 m); La Paz, Bolivia (12,000 ft; ≈3,650 m); Lhasa, Tibet Autonomous Region (12,100 ft; ≈3,700 m); Everest base camp, Nepal (17,700 ft; ≈5,400 m); and Mount Kilimanjaro, Tanzania (19,341 ft; ≈5,900 m). High-elevation environments expose travelers to cold, low humidity, increased ultraviolet radiation, and decreased air pressure, all of which can cause health problems. The biggest concern, however, is hypoxia, due to the decreased partial pressure of oxygen (PO2). At 10,000 ft (≈3,050 m), for example, the inspired PO2 is only 69% of that at sea level; acute exposure to this reduced PO2 can lower arterial oxygen saturation to 88%–91%.

The magnitude and consequences of hypoxic stress depend on the elevation, rate of ascent, and duration of exposure; host genetic factors may also contribute. Hypoxemia is greatest during sleep; day trips to high-elevation destinations with an evening return to a lower elevation are much less stressful on the body. Because of the key role of ventilation, travelers must avoid taking respiratory depressants at high elevations.

The human body can adjust to moderate hypoxia at elevations ≤17,000 ft (≈5,200 m) but requires time to do so. Some acclimatization to high elevation continues for weeks to months, but the acute process, which occurs over the first 3–5 days following ascent, is crucial for travelers. The acute phase is associated with a steady increase in ventilation, improved oxygenation, and changes in cerebral blood flow. Increased red cell production does not play a role in acute acclimatization, although a decrease in plasma volume over the first few days does increase hemoglobin concentration.

Altitude illness can develop before the acute acclimatization process is complete, but not afterwards. In addition to preventing altitude illness, acclimatization improves sleep, increases comfort and sense of well-being, and improves submaximal endurance; maximal exercise performance at high elevation will always be reduced compared to that at low elevation.

Travelers can optimize acclimatization by adjusting their itineraries to avoid going “too high too fast” (see  Box 4-08 ). Gradually ascending to elevation or staging the ascent provides crucial time for the body to adjust. For example, acclimatizing for a minimum of 2–3 nights at 8,000–9,000 ft (≈2,450–≈2,750 m) before proceeding to a higher elevation is markedly protective against acute mountain sickness (AMS). The Wilderness Medical Society recommends avoiding ascent to a sleeping elevation of ≥9,000 ft (≈2,750 m) in a single day; ascending at a rate of no greater than 1,650 ft (≈500 m) per night in sleeping elevation once above 9,800 ft (≈3,000 m); and allowing an extra night to acclimatize for every 3,300 ft (≈1,000 m) of sleeping elevation gain. These reasonable recommendations can still be too fast for some travelers and annoyingly slow for others.

Box 4-08 Acclimatization tips: a checklist for travelers

☐ Ascend gradually. ☐ Avoid going directly from low elevation to >9,000 ft (2,750 m) sleeping elevation in 1 day. ☐ Once above 9,000 ft (≈2,750 m), move sleeping elevation by no more than 1,600 ft (≈500 m) per day, and plan an extra day for acclimatization every 3,300 ft (≈1,000 m). ☐ Consider using acetazolamide to speed acclimatization if abrupt ascent is unavoidable. ☐ Avoid alcohol for the first 48 hours at elevation. ☐ If a regular caffeine user, continue using to avoid a withdrawal headache that could be confused with an altitude headache. ☐ Participate in only mild exercise for the first 48 hours at elevation. ☐ A high-elevation exposure (> 9,000 ft [≈2,750 m]) for ≥2 nights, within 30 days before the trip, is useful, but closer to the trip departure is better.

Risk to Travelers

Susceptibility and resistance to altitude illness are, in part, genetically determined traits, but there are no simple screening tests to predict risk. Training or physical fitness do not affect risk. A traveler’s sex plays a minimal role, if any, in determining predisposition. Children are as susceptible as adults; people aged >50 years have slightly less risk. Any unacclimatized traveler proceeding to a sleeping elevation of ≥8,000 ft (≈2,450 m)—and sometimes lower—is at risk for altitude illness. In addition, travelers who have successfully adjusted to one elevation are at risk when moving to higher sleeping elevations, especially if the elevation gain is >2,000–3,000 ft (600–900 m).

How a traveler previously responded to high elevations is the most reliable guide for future trips, but only if the elevation and rate of ascent are similar, and even then, this is not an infallible predictor. In addition to underlying, inherent baseline susceptibilities, a traveler’s risk for developing altitude illness is influenced by 3 main factors: elevation at destination, rate of ascent, and exertion ( Table 4-04 ). Creating an itinerary to avoid any occurrence of altitude illness is difficult because of variations in individual susceptibility, as well as in starting points and terrain. The goal for the traveler might not be to avoid all symptoms of altitude illness but to have no more than mild illness, thereby avoiding itinerary changes or the need for medical assistance or evacuation.

Table 4-04 Risk categories for developing acute mountain sickness (AMS)

RISK CATEGORY

DESCRIPTION

PROPHYLAXIS RECOMMENDATIONS

  • People with no prior history of altitude illness ascending to <9,000 ft (2,750 m)
  • People taking ≥2 days to arrive at 8,200–9,800 ft (≈2,500–3,000 m), with subsequent increases in sleeping elevation <1,600 ft (≈500 m) per day, and an extra day for acclimatization every 3,300 ft (1,000 m) increase in elevation

Acetazolamide prophylaxis generally not indicated

  • People with prior history of AMS and ascending to 8,200–9,200 ft (≈2,500–2,800 m) elevation (or above) in 1 day
  • People with no history of AMS ascending to >9,200 ft (2,800 m) elevation in 1 day
  • All people ascending >1,600 ft (≈500 m) per day (increase in sleeping elevation) at elevations >9,900 ft (3,000 m), but with an extra day for acclimatization every 3,300 ft (1,000 m)

Acetazolamide prophylaxis would be beneficial and should be considered

  • People with a history of AMS ascending to >9,200 ft (≈2,800 m) in 1 day
  • All people with a prior history of HAPE or HACE
  • All people ascending to >11,400 ft (≈3,500 m) in 1 day
  • All people ascending >1,600 ft (≈500 m) per day (increase in sleeping elevation) at elevations >9,800 ft (≈3,000 m), without extra days for acclimatization
  • People making very rapid ascents (e.g., <7-day ascent of Mount Kilimanjaro)

Acetazolamide prophylaxis strongly recommended

Abbreviations: HACE, high-altitude cerebral edema; HAPE, high-altitude pulmonary edema

Destinations of Risk

Some common high-elevation destinations require rapid ascent by a non-pressurized airplane to >11,000 ft (≈3,400 m), placing travelers in a high-risk category for AMS. A common travel medicine question is whether to recommend acetazolamide for travelers when gradual or staged acclimatization is not feasible. With rates of altitude illness approaching 30%–40% in these situations, a low threshold for chemoprophylaxis is advised. In some cases (e.g., Cusco and La Paz), travelers can descend to elevations much lower than the airport to sleep for 1–2 nights and then begin their ascent, perhaps obviating the need for medication.

Itineraries along some trekking routes in Nepal, particularly Everest base camps, push the limits of many people’s ability to acclimatize. Even on standard schedules, incidence of altitude illness can approach 30% at the higher elevations. Whenever possible, adding extra days to the trek can make for a more enjoyable and safer climb.

Altitude Illness Syndromes

Altitude illness is divided into 3 syndromes: acute mountain sickness (AMS), high-altitude cerebral edema (HACE), and high-altitude pulmonary edema (HAPE). Some clinicians consider high-altitude headache a separate entity because isolated headache can occur without the combined symptoms that define AMS.

Acute Mountain Sickness

AMS is the most common form of altitude illness, affecting 25% of all visitors sleeping at elevations >8,000 ft (≈2,450 m) in Colorado.

Diagnosis of AMS is based on a history of recent ascent to high elevation and the presence of subjective symptoms. AMS symptoms are like those of an alcohol hangover; headache is the cardinal symptom, usually accompanied by ≥1 of the following: anorexia, dizziness, fatigue, nausea, or, occasionally, vomiting. Uncommonly, AMS presents without headache. Symptom onset is usually 2–12 hours after initial arrival at a high elevation or after ascent to a higher elevation, and often during or after the first night. Preverbal children with AMS can develop loss of appetite, irritability, and pallor. AMS generally resolves within 12–48 hours if travelers do not ascend farther.

The condition is typically self-limited, developing and resolving over 1–3 days. Symptoms starting after 3 days of arrival to high elevation and without further ascent should not be attributed to AMS. AMS has no characteristic physical findings; pulse oximetry is usually within the normal range for the elevation, or slightly lower than normal.

The differential diagnosis of AMS is broad; common considerations include alcohol hangover, carbon monoxide poisoning, dehydration, drug intoxication, exhaustion, hyponatremia, and migraine. Travelers with AMS will improve rapidly with descent ≥1,000 ft (≈300 m), and this can be a useful indication of a diagnosis of AMS.

Although rarely available, supplemental oxygen at 1–2 liters per minute will relieve headaches within about 30 minutes and resolve other AMS symptoms over hours. The popular small, handheld cans of compressed oxygen can provide brief relief, but contain too little oxygen (5 liters at most) for sustained improvement. Travelers with AMS but without HACE or HAPE (both described below) can remain safely at their current elevation and self-treat with non-opiate analgesics (e.g., ibuprofen 600 mg or acetaminophen 500 mg every 8 hours) and antiemetics (e.g., ondansetron 4 mg orally disintegrating tablets).

Acetazolamide speeds acclimatization and resolves AMS, but is more commonly used and better validated for use as prophylaxis. Dexamethasone is more effective than acetazolamide at rapidly relieving the symptoms of moderate to severe AMS. If symptoms worsen while the traveler is at the same elevation, or despite supplemental oxygen or medication, descent is mandatory.

High-Altitude Cerebral Edema

As an encephalopathy, HACE is considered “end stage” AMS. Fortunately, HACE is rare, especially at elevations <14,000 ft (≈4,300 m). HACE is often a secondary consequence of the severe hypoxemia that occurs with HAPE.

Unlike AMS, HACE presents with neurological findings, particularly altered mental status, ataxia, confusion, and drowsiness, similar to alcohol intoxication. Focal neurologic findings and seizures are rare in HACE; their presence should lead to suspicion of an intracranial lesion, a seizure disorder, or hyponatremia. Other considerations for the differential diagnosis include carbon monoxide poisoning, drug intoxication, hypoglycemia, hypothermia, and stroke. Coma can ensue within 24 hours of onset.

In populated areas with access to medical care, HACE can be treated with supplemental oxygen and dexamethasone. In remote areas, initiate descent for anyone suspected of having HACE, in conjunction with dexamethasone and oxygen, if available. If descent is not feasible, supplemental oxygen or a portable hyperbaric device, in addition to dexamethasone, can be lifesaving. Coma is likely to ensue within 12–24 hours of the onset of ataxia in the absence of treatment or descent.

High-Altitude Pulmonary Edema

HAPE can occur by itself or in conjunction with AMS and HACE; incidence is roughly 1 per 10,000 skiers in Colorado, and ≤1 per 100 climbers at >14,000 ft (≈4,300 m).

Early diagnosis is key; HAPE can be more rapidly fatal than HACE. Initial symptoms include chest congestion, cough, exaggerated dyspnea on exertion, and decreased exercise performance. If unrecognized and untreated, HAPE progresses to dyspnea at rest and frank respiratory distress, often with bloody sputum. This typical progression over 1–2 days is easily recognizable as HAPE, but the condition sometimes presents only as central nervous system dysfunction, with confusion and drowsiness.

Rales are detectable in most victims. Pulse oximetry can aid in making the diagnosis; oxygen saturation levels will be at least 10 points lower in HAPE patients than in healthy people at the same elevation. Oxygen saturation values of 50%–70% are common. The differential diagnosis for HAPE includes bronchospasm, myocardial infarction, pneumonia, and pulmonary embolism.

In most circumstances, descent is urgent and mandatory. Administer oxygen, if available, and exert the patient as little as possible. If immediate descent is not an option, use of supplemental oxygen or a portable hyperbaric chamber is critical.

Patients with mild HAPE who have access to oxygen (e.g., at a hospital or high-elevation medical clinic) might not need to descend to a lower elevation and can be treated with oxygen over 2–4 days at the current elevation. In field settings, where resources are limited and there is a lower margin for error, nifedipine can be used as an adjunct to descent, oxygen, or portable hyperbaric oxygen therapy. A phosphodiesterase inhibitor can be used if nifedipine is not available, but concurrent use of multiple pulmonary vasodilators is not recommended. Descent and oxygen are much more effective treatments than medication.

Recommendations for use and dosages of medications to prevent and treat altitude illness are outlined in  Table 4-05 .

Table 4-05 Recommended medication dosing to prevent & treat altitude illness

Abbreviations: AMS, acute mountain sickness; HACE, high-altitude cerebral edema; HAPE, high-altitude pulmonary edema; IM, intramuscular; IV, intravenous; PO, by mouth; SR, sustained release. 1 This dose can also be used as an adjunct to dexamethasone for HACE treatment; dexamethasone remains the primary treatment for HACE. 2 Use only in conjunction with oral medications and not as monotherapy for HAPE prevention.

Acetazolamide

Mechanism of action.

When taken preventively, acetazolamide hastens acclimatization to high-elevation hypoxia, thereby reducing occurrence and severity of AMS. It also enhances recovery if taken after symptoms have developed. The drug works primarily by inducing a bicarbonate diuresis and metabolic acidosis, which stimulates ventilation and increases alveolar and arterial oxygenation. By using acetazolamide, high-elevation ventilatory acclimatization that normally takes 3–5 days takes only 1 day. Acetazolamide also eliminates central sleep apnea, or periodic breathing, which is common at high elevations, even in those without a history of sleep disorder breathing.

An effective dose for prophylaxis that minimizes the common side effects of increased urination and paresthesia of the fingers and toes is 125 mg every 12 hours, beginning the day before ascent and continuing the first 2 days at elevation, and longer if ascent continues. Acetazolamide can also be taken episodically for symptoms of AMS, as needed. To date, the only dose studied for treatment is 250 mg (2 doses taken 8 hours apart), although the lower dosage used for prevention has anecdotally been successful. The pediatric dose is 5 mg/kg/day in divided doses, up to 125 mg, twice a day.

Adverse & Allergic Reactions

 Allergic reactions to acetazolamide are uncommon. Since acetazolamide is a sulfonamide derivative, cross-sensitivity between acetazolamide, sulfonamides, and other sulfonamide derivatives is possible.

Dexamethasone

Dexamethasone is effective for preventing and treating AMS and HACE and might prevent HAPE as well. Unlike acetazolamide, if the drug is discontinued at elevation before acclimatization, mild rebound can occur. Acetazolamide is preferable to prevent AMS while ascending, and dexamethasone generally should be reserved for treatment, usually as an adjunct to descent. The adult dose is 4 mg every 6 hours; rarely is it needed for more than 1–2 days. An increasing trend is to use dexamethasone for “summit day” on high peaks (e.g., Aconcagua and Kilimanjaro) to prevent abrupt altitude illness.

Recent studies have shown that taking ibuprofen 600 mg every 8 hours helps prevent AMS, although not quite as effectively as acetazolamide. Ibuprofen is, however, available over the counter, inexpensive, and well tolerated.

Nifedipine both prevents and ameliorates HAPE. For prevention, nifedipine is generally reserved for people who are particularly susceptible to the condition. The adult dose for prevention or treatment is 30 mg of extended release every 12 hours, or 20 mg every 8 hours.

Phosphodiesterase-5 Inhibitors

Phosphodiesterase-5 inhibitors selectively lower pulmonary artery pressure, with less effect on systemic blood pressure than nifedipine. Tadalafil, 10 mg taken twice a day during ascent, can prevent HAPE. It is also being studied as a possible treatment.

The main point of instructing travelers about altitude illness is not to eliminate the possibility of mild illness but to prevent death or evacuation. Because the onset of symptoms and the clinical course are sufficiently slow and predictable, there is no reason for anyone to die from altitude illness unless they are trapped by weather or geography in situations where descent is impossible. Travelers can adhere to 3 rules to help prevent death or serious consequences from altitude illness:

  • Know the early symptoms of altitude illness and be willing to acknowledge when symptoms are present.
  • Never ascend to sleep at a higher elevation when experiencing symptoms of altitude illness, no matter how minor the symptoms seem.
  • Descend if the symptoms become worse while resting at the same elevation.

For trekking groups and expeditions going into remote high-elevation areas, where descent to a lower elevation could be problematic, a pressurization bag (e.g., the Gamow bag) can be beneficial. A foot pump produces an increased pressure of 2 lb/in2, mimicking a descent of 5,000–6,000 ft (≈1,500–1,800 m) depending on the starting elevation. The total packed weight of bag and pump is about 14 lb (6.5 kg).

Preexisting Medical Conditions

Travelers with preexisting medical conditions must optimize their treatment and have their conditions stable before departure. In addition, these travelers should have plans for dealing with exacerbation of their conditions at high elevations. Travelers with underlying medical conditions (e.g., coronary artery disease, any form of chronic pulmonary disease or preexisting hypoxemia, obstructive sleep apnea [OSA], or sickle cell trait)—even if well controlled—should consult a physician familiar with high-elevation medical issues before undertaking such travel ( Table 4-06 ).

Clinicians advising travelers should know that in most high-elevation resorts and cities, “home” oxygen is readily available. In North America, this requires a prescription that the traveler can carry, or oxygen can be arranged beforehand. Supplemental oxygen, whether continuous, episodic, or nocturnal, depending on the circumstances, is very effective at restoring oxygenation to low elevation values and eliminates the risk for altitude illness and exacerbation of preexisting medical conditions.

Table 4-06 Ascent risk associated with various underlying medical conditions & risk factors

LIKELY NO EXTRA RISK

CAUTION REQUIRED 1

ASCENT CONTRAINDICATED

  • Asthma (well-controlled)
  • Children and adolescents
  • Chronic obstructive pulmonary disease (mild)
  • Coronary artery disease (following revascularization)
  • Diabetes mellitus
  • Hypertension (controlled)
  • Neoplastic diseases
  • Obesity (Class 1/Class 2) 2
  • Obstructive sleep apnea (mild/ moderate)
  • Pregnancy (low-risk)
  • Psychiatric disorders (stable)
  • Seizure disorder (controlled)
  • Angina (stable)
  • Arrhythmias (poorly controlled)
  • Chronic obstructive pulmonary disease (moderate)
  • Coronary artery disease (nonrevascularized)
  • Cystic fibrosis (FEV1 30%–50% predicted)
  • Heart failure (compensated)
  • Hypertension (poorly controlled)v Infants <6 weeks old
  • Obesity (Class 3) 3
  • Obstructive sleep apnea (severe)
  • Pulmonary hypertension (mild)
  • Radial keratotomy surgery
  • Seizure disorder (poorly controlled)
  • Sickle cell trait
  • Angina (unstable)
  • Asthma (unstable, poorly controlled)
  • Cerebral space–occupying lesions
  • Cerebral vascular aneurysms or arteriovenous malformations (untreated, high-risk)
  • Chronic obstructive pulmonary disease (severe/very severe)
  • Cystic fibrosis (FEV1 <30% predicted)
  • Heart failure (decompensated)
  • Myocardial infarction or stroke (<90 days before ascent)
  • Pregnancy (high-risk)
  • Pulmonary hypertension (pulmonary artery systolic pressure >60 mm Hg)
  • Sickle cell anemia

Abbreviations: : FEV1, forced expiratory volume in 1 second

1 Travelers with these conditions most often require consultation with a physician experienced in high-altitude medicine and a comprehensive management plan.

2 Class 1 obesity: Body Mass Index (BMI) of 30 to <35; Class 2 obesity: BMI of 35 to <40

3 Class 3 obesity: BMI of ≥40.

Diabetes Mellitus

Travelers with diabetes can travel safely to high elevations, but they must be accustomed to exercise if participating in strenuous activities at elevation and carefully monitor their blood glucose. Diabetic ketoacidosis can be triggered by altitude illness and can be more difficult to treat in people taking acetazolamide. Not all glucose meters read accurately at high elevations.

Obstructive Sleep Apnea

Travelers with sleep disordered breathing who are planning high-elevation travel should receive acetazolamide. Those with mild to moderate OSA who are not hypoxic at home might do well without a continuous positive airway pressure (CPAP) device, while those with severe OSA should be advised to avoid high-elevation travel unless they receive supplemental oxygen in addition to their CPAP. Oral appliances for OSA can be useful adjuncts when electrical power is unavailable.

There are no studies or case reports describing fetal harm among people who briefly travel to high elevations during their pregnancy. Nevertheless, clinicians might be prudent to recommend that pregnant people do not stay at sleeping elevations >10,000 ft (≈3,050 m). Travel to high elevations during pregnancy warrants confirmation of good maternal health and verification of a low-risk gestation. Advise pregnant travelers of the dangers of having a pregnancy complication in remote, mountainous terrain.

Radial Keratotomy

Most people do not have visual problems at high elevations. At very high elevations, however, some people who have had radial keratotomy procedures might develop acute farsightedness and be unable to care for themselves. LASIK and other newer procedures may produce only minor visual disturbances at high elevations.

The following authors contributed to the previous version of this chapter: Peter H. Hackett, David R. Shlim

Bibliography

Bartsch P, Swenson ER. Acute high-altitude illnesses. N Engl J Med. 2013;369(17):1666–7. 

Hackett PH, Luks AM, Lawley JS, Roach RC. High-altitude medicine and pathophysiology. In: Auerbach PS, editor. Wilderness medicine, 7th edition. Philadelphia: Elsevier; 2017. pp. 8–28. 

Hackett PH, Roach RC. High altitude cerebral edema. High Alt Med Biol. 2004;5(2):136–46. 

Luks AM, Auerbach PS, Freer L, Grissom CK, Keyes LE, McIntosh SE, et al. Wilderness Medical Society clinical practice guidelines for the prevention and treatment of acute altitude illness: 2019 update. Wilderness Environ Med. 2019;30(4S):S3–18. 

Luks AM, Hackett PH. High altitude and preexisting medical conditions. In: Auerbach PS, editor. Wilderness medicine, 7th edition. Philadelphia: Elsevier; 2017. pp. 29–39. 

Luks AM, Hackett PH. Medical conditions and high-altitude travel. N Engl J Med. 2022;386(4):364–73. 

Luks AM, Swenson ER.Medication and dosage considerations in the prophylaxis and treatment of high-altitude illness. Chest. 2008;133(3):744–55. 

Meier D, Collet TH, Locatelli I, Cornuz J, Kayser B, Simel DL, Sartori C. Does this patient have acute mountain sickness? The rational clinical examination systematic review. JAMA. 2017;318(18):1810–19. 

Roach RC, Lawley JS, Hackett PH. High-altitude physiology. In: Auerbach PS, editor. Wilderness medicine, 7th edition. Philadelphia: Elsevier; 2017. pp. 2–8. 

Woolcott OO. The Lake Louise Acute Mountain Sickness score: still a headache. High Alt Med Biol. 2021;22(4):351–2.

File Formats Help:

  • Adobe PDF file
  • Microsoft PowerPoint file
  • Microsoft Word file
  • Microsoft Excel file
  • Audio/Video file
  • Apple Quicktime file
  • RealPlayer file
  • Zip Archive file

Exit Notification / Disclaimer Policy

  • The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
  • Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
  • You will be subject to the destination website's privacy policy when you follow the link.
  • CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
  • Help and resources
  • Register for My Account
  • Sign in to My Account

Australian Government Coat of Arms

Federal Register of Legislation

Known issues.

Thank you for your patience as we work to resolve bugs and issues on the new Register. To see if your issue has already been reported, please view the list of known issues .

  • All versions
  • Interactions

Tourism Australia (Repeal and Transitional Provisions) Act 2004

  • Department of Foreign Affairs and Trade

Legislation text

  • Tourism Australia (Repeal and Transitional Provisions) Act 2004 - [Act Compilation]

IMAGES

  1. Ministry of Tourism

    tourism act 2004

  2. National Tourism Act Q & A

    tourism act 2004

  3. PPT

    tourism act 2004

  4. PPT

    tourism act 2004

  5. PPT

    tourism act 2004

  6. PPT

    tourism act 2004

COMMENTS

  1. Federal Register of Legislation

    Latest version. C2016C00443 (C05) 05 March 2016. View document. Table of contents. Tourism Australia Act 2004 - [Act Compilation]

  2. PDF The Tourism Act 2004

    This Act may be cited as the Tourism Act 2004. 2. Interpretation In this Act - "agent" means a person in Mauritius who is authorised in writing by a licensee to represent the licensee in any application under this Act or any legal proceedings in Mauritius; "authorised officer" means an officer authorised by the Permanent Secretary under

  3. TOURISM AUSTRALIA ACT 2004

    TOURISM AUSTRALIA ACT 2004. Search this Act. . Resolutions Division 3--Advisory panels. Advisory panels . Procedures of advisory panels etc. . Disclosure of interests at meetings . Resignation . Other terms and conditions PART 4--CORPORATE PLANNING AND ACCOUNTABILITYDivision 1--Corporate plan and annual operational plan.

  4. Our Vision

    Tourism Australia Act 2004. Tourism Australia is a corporate Commonwealth entity and was established by the Tourism Australia Act 2004. Under section 6 of the Tourism Australia Act 2004, Tourism Australia's main objectives are: To influence people to travel to Australia, including for events, ...

  5. Tourism Australia Act 2004

    Federal Register of Legislation - Australian Government. Skip to primary navigation Skip to primary content. Australian Government Federal Register of Legislation Skip to Content

  6. Tourism Australia Act 2004.

    Tourism Australia Act 2004. This content is exclusively provided by FAO / FAOLEX. Tourism Australia Act 2004. Country. Australia. Type of law. Legislation. Date of original text. 2004. Source ... Abstract. This Act establishes Tourism Australia as a body corporate, defines its functions and powers and provides with respect to its administration ...

  7. TOURISM ACT OF 2004

    tourism act of 2004 tourism act of 2004. senate bill no. 1725, 13th congress of the republic. long title. an act strengthening, reorganizing and streamlining the department of tourism, and declaring a national policy for tourism as the primary engine of investment, employment, growth and national development. short title ...

  8. Tourism Australia

    Tourism Australia was created in 2004 by the Tourism Australia Act (Cth) as a merger of four existing tourism organisations - the Australian Tourist Commission, the Bureau of Tourism Research, and the Tourism Forecasting Council, and See Australia. Tourism Australia describes itself as the successor of the Australian Tourist Commission, and hence celebrated what would be the commission's 50 ...

  9. PDF The Tourism Authority Act 2006

    THE TOURISM AUTHORITY ACT 2006 Act 32/2006 Proclaimed by [Proclamation No. 5 of 2007] w.e.f 1st May 2007 Government Gazette of Mauritius No. 121 of 30 December, 2006 I assent SIR ANEROOD JUGNAUTH President of the Republic 27th December 2006 _____ ARRANGEMENT OF SECTIONS Section PART I - PRELIMINARY 1. Short title 2. Interpretation PART II ...

  10. Tourism Act 2004 (No. 19 of 2004).

    Tourism Act 2004 (No. 19 of 2004). An Act to make better provision for the regulation of the tourism industry with a view to promoting its development in a sustainable manner. This Act shall come into operation on a day to be fixed by Proclamation. This Act provides rules for the tourist industry and makes provision for the establishment of the ...

  11. Tourism Act 2004 (No. 19 of 2004).

    This Act provides rules for the tourist industry and makes provision for the establishment of the Tourist Authority and the licensing of tourist enterprises. Tourism Act 2004 (No. 19 of 2004). | InforMEA

  12. Tourism Australia Act 2004

    Act No. 74 of 2004 as amended, taking into account amendments up to Acts and Instruments (Framework Reform) (Consequential Provisions) Act 2015: An Act to establish Tourism Australia, and for related purposes: Administered by: Foreign Affairs and Trade

  13. TOURISM FIJI ACT 2004

    This website is managed by the Office of the Attorney-General ( 'Office' ) for the purpose of providing information free of charge for the benefit of the public. This website contains information that is intended to simplify the law for ease of comprehension. Errors or omissions can occur in the preparation of web pages and materials may be ...

  14. PDF WESTERN CAPE TOURISM ACT, 2004

    TOURISM ACT, 2004 PROVINSIE WES-KAAP WES-KAAPSE WET OPTOERISME, 2004 No 1, 2004. ACT ... Western Cape Tourism Act, 1997; and to provide for matters incidental thereto. PREAMBLE WHEREAS the Western Cape Provincial Government (''the Government'') is committed to the economic development of the Province of the Western Cape (''the

  15. PDF REPUBLIC ACT NO. 9593 CHAPTER I. GENERAL PROVISIONS

    - This Act shall be known as "The Tourism Act of 2009." SECTION 2. Declaration of Policy. - The State declares tourism as an indispensable element of the national economy and an industry of national interest and importance, which must be harnessed as an engine of socio-economic growth and cultural affirmation to generate

  16. Legislations

    The Financial Services Act 2007; Tourism Act 2004; Tourism Authority Act 2006; VAT; The Value Added Tax Act 1998; Value Added Tax (Solidarity Levy) Regulations 2006; Value Added Tax Regulations 1998; Australia. June 1995 Australian Chamber of Commerce and Industry (ACCI) Austria. September 2014

  17. Tourism Australia Act 2004

    About this compilation This compilation This is a compilation of the Tourism Australia Act 2004 that shows the text of the law as amended and in force on 5 March 2016 (the compilation date). The notes at the end of this compilation (the endnotes) include information about amending laws and the amendment history of provisions of the compiled

  18. Federal Register of Legislation

    Public Governance, Performance and Accountability (Consequential and Transitional Provisions) Act 2014. Tourism Australia Act 2004. Superseded. 29/Mar/2012. C2012C00363. 27/Dec/2011. 30/Jun/2014. Acts Interpretation Amendment Act 2011. Tourism Australia Act 2004.

  19. PDF The Tourism Act, 2008

    tour guide. (2) Where the Director is satisfied that the tour guide has contravened any ofthe provisions of this Act, he may reprimand, suspend or deregister the tour guide. Director may restrict a. 45.-(l) The Director may order restriction of activities of any tour guide in respect of an area specified in the order.

  20. Tourism Fiji

    Tourism Fiji is a Fijian government marketing agency responsible for promoting Fiji as a tourism destination abroad. Formerly known as the Fiji Visitors Bureau, the agency was established under the Tourism Fiji Act 2004 and is under the jurisdiction of the Ministry of Commerce, Trade, Tourism and Transport.. The agency's head office which is located in Nadi, also maintains a presence overseas ...

  21. PDF Tourism Act of 2009 (RA9593)

    The Department of Tourism (DOT) commemorates the 10th year since Republic Act 9593, better known as the Tourism Act of 2009, was signed into law. Enacted on May 12, 2009, by President Gloria Macapagal-Arroyo in Cebu City, R.A. 9593 recognized tourism as an indispensable element of the national economy and an industry of national interest and ...

  22. Tourism Australia Act 2004

    Tourism Australia Act 2004 - C2004A01307; In force - Superseded Version; View Series; Act No. 74 of 2004 as made: An Act to establish Tourism Australia, and for related purposes: Administered by: Foreign Affairs and Trade: Originating Bill: Tourism Australia Bill 2004: Date of Assent 23 Jun 2004 ...

  23. High Elevation Travel & Altitude Illness

    Hackett PH, Roach RC. High altitude cerebral edema. High Alt Med Biol. 2004;5(2):136-46. Luks AM, Auerbach PS, Freer L, Grissom CK, Keyes LE, McIntosh SE, et al. Wilderness Medical Society clinical practice guidelines for the prevention and treatment of acute altitude illness: 2019 update. Wilderness Environ Med. 2019;30(4S):S3-18.

  24. Tourism Australia (Repeal and Transitional Provisions) Act 2004

    An Act to repeal the Australian Tourist Commission Act 1987, to deal with transitional matters arising from the repeal of that Act and the enactment of the Tourism Australia Act 2004, and for related purposes. Part 1 — Preliminary. 1 Short title [see Note 1] This Act may be cited as the Tourism Australia (Repeal and Transitional Provisions) Act 2004.